The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23, 2026, to recommend BPC-157 for inclusion on the Section 503A bulks list, overriding agency staff concerns over immunogenicity and limited human data. This advisory step advances the peptide from its current Category 2 status—where compounding pharmacies are generally barred due to safety risks—toward Category 1 eligibility for patient-specific compounding while evaluation continues. Full reclassification requires notice-and-comment rulemaking, a process that typically spans 8–12 months and is not guaranteed to follow the panel's narrow recommendation. No subsequent FDA action has been announced as of early August 2026. Traders are monitoring docket comments, agency timelines, and any shifts in administration priorities that could accelerate or delay formal placement.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日新規
2026/08/31
2026年8月31日
16%
2026年12月31日
50%
$2,565 Vol.
2026年8月31日
$859 Vol.
16%
2026年12月31日
$1,706 Vol.
50%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23, 2026, to recommend BPC-157 for inclusion on the Section 503A bulks list, overriding agency staff concerns over immunogenicity and limited human data. This advisory step advances the peptide from its current Category 2 status—where compounding pharmacies are generally barred due to safety risks—toward Category 1 eligibility for patient-specific compounding while evaluation continues. Full reclassification requires notice-and-comment rulemaking, a process that typically spans 8–12 months and is not guaranteed to follow the panel's narrow recommendation. No subsequent FDA action has been announced as of early August 2026. Traders are monitoring docket comments, agency timelines, and any shifts in administration priorities that could accelerate or delay formal placement.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
マーケット開始日： Jun 22, 2026, 10:10 PM ET
音量
$2,565終了日
2026/12/31マーケット開始日
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23, 2026, to recommend BPC-157 for inclusion on the Section 503A bulks list, overriding agency staff concerns over immunogenicity and limited human data. This advisory step advances the peptide from its current Category 2 status—where compounding pharmacies are generally barred due to safety risks—toward Category 1 eligibility for patient-specific compounding while evaluation continues. Full reclassification requires notice-and-comment rulemaking, a process that typically spans 8–12 months and is not guaranteed to follow the panel's narrow recommendation. No subsequent FDA action has been announced as of early August 2026. Traders are monitoring docket comments, agency timelines, and any shifts in administration priorities that could accelerate or delay formal placement.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
音量
$2,565終了日
2026/12/31マーケット開始日
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23, 2026, to recommend BPC-157 for inclusion on the Section 503A bulks list, overriding agency staff concerns over immunogenicity and limited human data. This advisory step advances the peptide from its current Category 2 status—where compounding pharmacies are generally barred due to safety risks—toward Category 1 eligibility for patient-specific compounding while evaluation continues. Full reclassification requires notice-and-comment rulemaking, a process that typically spans 8–12 months and is not guaranteed to follow the panel's narrow recommendation. No subsequent FDA action has been announced as of early August 2026. Traders are monitoring docket comments, agency timelines, and any shifts in administration priorities that could accelerate or delay formal placement.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問